Literature DB >> 27518324

Efficient Routes to a Diverse Array of Amino Alcohol-Derived Chiral Fragments.

Sina Haftchenary1,2, Shawn D Nelson1,2, Laura Furst1, Sivaraman Dandapani1, Steven J Ferrara1, Žarko V Bošković1,2, Samuel Figueroa Lazú1, Adrian M Guerrero1, Juan C Serrano1, DeMarcus K Crews1, Cristina Brackeen1, Jeffrey Mowat3, Thomas Brumby3, Marcus Bauser3, Stuart L Schreiber1,2,4, Andrew J Phillips5.   

Abstract

Efficient syntheses of chiral fragments derived from chiral amino alcohols are described. Several unique scaffolds were readily accessed in 1-5 synthetic steps leading to 45 chiral fragments, including oxazolidinones, morpholinones, lactams, and sultams. These fragments have molecular weights ranging from 100 to 255 Da and are soluble in water (0.085 to >15 mM).

Entities:  

Keywords:  amino alcohols; chiral fragments; drug discovery; fragment-based lead discovery

Mesh:

Substances:

Year:  2016        PMID: 27518324      PMCID: PMC5022782          DOI: 10.1021/acscombsci.6b00050

Source DB:  PubMed          Journal:  ACS Comb Sci        ISSN: 2156-8944            Impact factor:   3.784


Introduction

Fragment-based ligand discovery (FBLD) has emerged as a valuable complement to high-throughput screening over the past decade and has produced clinical-stage candidates (Figure ), as well as the FDA-approved drugs vemurafenib and venetoclax.[1−3] The rise of FBLD has been underpinned by methodological advances in the discovery of fragments hits by biophysical screening methods such as nuclear magnetic resonance (NMR), surface plasmon resonance (SPR), calorimetry, mass-spectrometry (MS) and X-ray crystallography. In contrast, the chemical features and optimal properties of fragments remain an area of debate and unresolved challenges.[2] For instance, some fragments available from commercial vendors are limited by their poor solubility in water and lack of appropriate functionality for rapid fragment growth. Many commercial fragment collections are enriched in aromatic and heteroaromatic compounds, therefore expanding existing fragment chemical space by making compounds with a higher proportion of sp3-hybridized atoms may be beneficial.[3,4] Here, we describe initial efforts to access sp3-rich chiral fragments from chiral amino alcohols, a class of starting materials advantaged by commercial availability, diversity of additional functional groups, and well-understood reactivity with electrophiles.
Figure 1

Representative examples of clinical-stage and approved compounds originating from FBLD.

Representative examples of clinical-stage and approved compounds originating from FBLD.

Results and Discussion

We synthesized low molecular weight 5-, 6- and 7-membered cyclic scaffolds from 1,2-amino alcohols and measured their aqueous solubilities to evaluate their potential for use in FBLD. Since thousands of enantioenriched 1,2-amino alcohols are already commercially available or easily obtained through modern asymmetric synthesis,[5−9] chemical pathways and solubility data reported in this article will encourage the production of more diverse and larger sub-libraries. A representative selection of nine amino alcohols (Figure ) were selected to pilot the synthesis of diverse skeletons. Amino alcohols 1-4 were chosen to explore the effects of both aliphatic and aromatic substituents on the carbon atom alpha to the amine or alcohol across all scaffolds. Amino alcohols 5-7[10] explore the role of secondary amines while 8 and 9(11) represent simple amino alcohols that can result in polar spirocyclic fragments with additional heteroatoms. The goal of this study was to “de-risk” the chemistry involved in accessing various scaffolds with a limited set of amino alcohols and to evaluate the suitability of the resulting fragments for FBLD by experimentally determining their aqueous solubilities.
Figure 2

Structures of the representative chiral (or spiro) amino alcohol building blocks.

Structures of the representative chiral (or spiro) amino alcohol building blocks. Oxazolidinones 10a–g (Scheme ) were straightforward to prepare by previously reported approaches or modifications thereof.[12−18] In general, amino alcohols could be treated with carbonyldiimidazole and triethylamine (Et3N), followed by heating at 60 °C overnight to afford the desired compounds in low to high yields (28–85%). Alternatively, oxazolidinones 10a and 10b were obtained in high yields (84%) by treatment of the neat amino alcohol with diethylcarbonate and a substoichiometric amount of sodium ethoxide at temperatures between 135 and 150 °C. Morpholinones 11a–f were synthesized by a similarly direct process in which the amino alcohols were treated with sodium hydride and ethyl chloroacetate at room temperature overnight to afford the morpholinone analogs in variable yields (19–82%).[19] Morpholinones 11g and 11h were prepared using an alternative methodology in which the amino alcohols were treated with chloroacetyl chloride at room temperature, followed by intramolecular cyclization with sodium hydride at temperatures between 65 and 80 °C (18–22%).[20] Conveniently, morpholinones 11c, 11d, 11f, and 11g, were transformed to morpholines 11i–l in low to good yields (23–75%) by direct reduction of the lactam with lithium aluminum hydride at room temperature (those not shown were not attempted or were readily commercially available).[21,22]
Scheme 1

Reaction conditions: (A) CDI, Et3N, THF, 60 °C, 24 h, 27–85%; (B) NaH; ethyl chloroacetate, THF, rt, 24 h, 19–82%; (C) (i) Boc2O, Et3N, DCM, 0 °C, rt, 24 h, 83-99%; (ii) SOCl2, imidazole, Et3N, DCM, −40 °C, 2 h; then at rt for 2 h, 55–94%; (iii) RuCl3, NaIO4, MeCN:H2O (1:1), 0 °C to rt, 3 h, 31–95%; (iv) TFA, DCM, rt, 24 h, 66–90%; (D) (i) ClCH2SO2Cl, Et3N, DCM, 0 °C to rt, 6 h, 34-84%; (ii) PMB-Br, K2CO3, DMF, rt, 1 h, 17–89%; (iii) Cs2CO3, DMF, 80 °C, 24 h, 55–78%; (iv) CAN, MeCN:H2O (9:1), rt, 24 h, 24–78%; (E) (i) Boc2O, Et3N, DCM, 0 °C, rt, 24 h, 83–99%; (ii) t-butyl acrylate, Cs2CO3, t-BuOH, 24 h, 75–99%; (iii) 4.0 M HCl in dioxane, 24 h, 97–99%; (iv) T3P, Et3N, dioxane, 24 h, rt, 33–86%; (F) (i) TBS-Cl, Et3N, DCM, 0 °C to rt, 24 h, 71–95%; (ii) chloroethane sulfonyl chloride, Et3N, 0 °C to rt, 2 h, 75–95%; (iii) MeI, K2CO3, MeCN, 72 h, 70–90%; (iv) TBAF, THF, 2 h, 38–91%.

Reaction conditions: (A) CDI, Et3N, THF, 60 °C, 24 h, 27–85%; (B) NaH; ethyl chloroacetate, THF, rt, 24 h, 19–82%; (C) (i) Boc2O, Et3N, DCM, 0 °C, rt, 24 h, 83-99%; (ii) SOCl2, imidazole, Et3N, DCM, −40 °C, 2 h; then at rt for 2 h, 55–94%; (iii) RuCl3, NaIO4, MeCN:H2O (1:1), 0 °C to rt, 3 h, 31–95%; (iv) TFA, DCM, rt, 24 h, 66–90%; (D) (i) ClCH2SO2Cl, Et3N, DCM, 0 °C to rt, 6 h, 34-84%; (ii) PMB-Br, K2CO3, DMF, rt, 1 h, 17–89%; (iii) Cs2CO3, DMF, 80 °C, 24 h, 55–78%; (iv) CAN, MeCN:H2O (9:1), rt, 24 h, 24–78%; (E) (i) Boc2O, Et3N, DCM, 0 °C, rt, 24 h, 83–99%; (ii) t-butyl acrylate, Cs2CO3, t-BuOH, 24 h, 75–99%; (iii) 4.0 M HCl in dioxane, 24 h, 97–99%; (iv) T3P, Et3N, dioxane, 24 h, rt, 33–86%; (F) (i) TBS-Cl, Et3N, DCM, 0 °C to rt, 24 h, 71–95%; (ii) chloroethane sulfonyl chloride, Et3N, 0 °C to rt, 2 h, 75–95%; (iii) MeI, K2CO3, MeCN, 72 h, 70–90%; (iv) TBAF, THF, 2 h, 38–91%. Sulfamidates 12a, 12b, and 12d were obtained by a four step sequence as outlined in Scheme .[23,24] Protection of the amine as the t-butoxycarbonyl (Boc) carbamate and reaction with thionyl chloride in the presence of imidazole and triethylamine at −40 °C afforded the desired cyclic sulfamidite in modest to high yields (55–94%). The sulfamidite was subsequently oxidized using catalytic ruthenium(III) chloride and an excess of sodium periodate in acetonitrile to afford the protected sulfamidates. Removal of the Boc protecting group with trifluoroacetic acid afforded the desired sulfamidates (12a, 12b, and 12d) in good to high yields (66–90%). The N-benzylated sulfamidate 12c was prepared with an analogous approach in modest yields (40%) by treatment of the N-benzyl amino alcohol with thionyl chloride, imidazole, and triethylamine at –40 °C, followed by oxidation with catalytic ruthenium(III) chloride and sodium periodate in acetonitrile (products derived from amino alcohols 1, 2, 7, 8, and 5 were not investigated). Our initial efforts to synthesize low molecular weight sultams commenced with the straightforward preparation of the α-chlorosulfonamide by treatment of amino alcohols with chloromethanesulfonyl chloride under basic conditions (20–84%). In accordance with previous observations on analogous systems by Borcard and colleagues,[25] we observed that direct cyclization attempts from this intermediate were ineffective and resulted in poor conversion and polymeric products. These synthetic challenges were readily overcome by selective protection of the sulfonamide nitrogen with a p-methoxybenzyl (PMB) group (17–98%) and subsequent cyclization under basic conditions (55–87%). The PMB protecting group was readily removed by ceric ammonium nitrate (CAN) in a 9:1 mixture of acetonitrile and water to produce 13a-g in low to good yields (24–78%); 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) was wholly ineffective for this deprotection. Limited literature precedent exists for the synthesis of 7-membered chiral lactams from amino alcohols.[26] Treatment of amino alcohols with acryloyl chloride followed by intramolecular oxa-conjugate addition has been studied for accessing 7-membered lactams but this approach is plagued by ineffective cyclizations and poor yields.[27,28] Here, we report an efficient route that furnishes the desired analogues, 14a–f, 14h, and 14i in four-steps. After N-Boc protection of the amino alcohols, treatment with t-butyl acrylate and cesium carbonate (Cs2CO3) in t-butanol (t-BuOH) at 50 °C yielded the desired conjugate addition products in good to high yields (75–99%). Next, a global deprotection was performed using hydrochloric acid (HCl) in dioxane to afford the amine hydrochloride salts in high yields yields (97–100%). The intermediate salts were surveyed for optimal intramolecular amidation conditions which were achieved upon treatment with propylphosphonic anhydride (T3P) in dioxane and stirring at room temperature for 24 h. As such, analogs 14a–f, 14h, and 14i were prepared in modest to high yields (33–83%). Compared to existing methods for accessing these 7-membered rings that require high heat and pressure,[29] the T3P-mediated cyclization reported here proceeds at ambient conditions and hence represents an advance. Given the mild conditions, we anticipate broader substrate scope for the T3P-mediated access to 7-membered ring lactams. The 7-membered sultams (Scheme , 15a–h) were synthesized by a modified protocol in accord with the precedent of Zhou and colleagues.[30,31] After protection of the alcohol as the t-butyldimethylsilyl (TBS) ether, treatment with 2-chloroethanesulfonyl chloride in the presence of excess Et3N yielded the vinyl sulfonamide intermediates in good to high yields (60–98%). In order to promote intramolecular cyclization, all secondary vinyl sulfonamides were methylated to afford N-Me-sulfonamides (70-90%). Lastly, intramolecular cyclizations were achieved in a one-pot fashion via tetra-n-butylammonium fluoride (TBAF) promoted TBS cleavage, followed by hetero-conjugate addition to afford the desired sultams 15a–h in low to high yields (37–97%). No reaction was observed with secondary sulfonamides. We postulate the favorable s-trans conformation of the secondary sulfonamides hinders the cyclization reaction. Overall, we prepared a library of 50 (Figure , Schemes and 2) chiral amino alcohol-derived fragments using the methodologies described above and amino alcohols chosen from the set shown in Figure . All of the prepared compounds were evaluated in an aqueous solubility assay using either LC-MS/MS or UV for quantification.[32] As displayed in Figure and Scheme , the aqueous solubilities ranged from 0.085 to >15 mM.
Figure 3

Readily prepared pilot collection of 45 chiral amino alcohol-derived fragments presented with overall yields and solubility data (nd = not determined). Compounds with >0.50 mM solubilities were exposed to an assay with a 0.50 mM upper limit (see Supporting Information). (a) Amino alcohol 7 was explored solely for the 7-membered lactam family of compounds.

Scheme 2

Synthetic Route to Expanded Product Library Derived from 11c as a Representative Example

Reaction conditions: (i) Lawesson’s reagent, THF, 55 °C, 3 h, 78%; (ii) RCONHNH2, t-BuOH, 135 °C, 24 h, 39-63%. Aqueous solubility data is show in parentheses.

Readily prepared pilot collection of 45 chiral amino alcohol-derived fragments presented with overall yields and solubility data (nd = not determined). Compounds with >0.50 mM solubilities were exposed to an assay with a 0.50 mM upper limit (see Supporting Information). (a) Amino alcohol 7 was explored solely for the 7-membered lactam family of compounds.

Synthetic Route to Expanded Product Library Derived from 11c as a Representative Example

Reaction conditions: (i) Lawesson’s reagent, THF, 55 °C, 3 h, 78%; (ii) RCONHNH2, t-BuOH, 135 °C, 24 h, 39-63%. Aqueous solubility data is show in parentheses. We then investigated the utility of our chiral fragments as starting points for further diversification. For example, compound 11c was transformed into an array of extended triazole products via thiolactam intermediates (Scheme ). Following a modified procedure from Wishka and Walker,[33] two thiolactams 16 and 17 were obtained in 78 and 48% yield, respectively, upon treatment with Lawesson’s reagent. Conversion of 16 into triazoles 18–20 was accomplished by heating in an excess of the appropriate hydrazide in t-BuOH for 24 h (39-63%).[34]

Conclusion

In conclusion, we have developed facile and convenient synthetic routes to several families of unique and water-soluble amino alcohol-derived chiral fragments. A total of 45 compounds including chiral morpholines, lactams, sultams, and sulfamidates were synthesized in 1-5 synthetic steps. These chiral fragments are characterized by low molecular weights (100–255 Da) and aqueous solubilities in the range of 0.085 to >15 mM which are important criteria among compounds useful for FBLD.[35]
  33 in total

1.  Oxetanes as promising modules in drug discovery.

Authors:  Georg Wuitschik; Mark Rogers-Evans; Klaus Müller; Holger Fischer; Björn Wagner; Franz Schuler; Liudmila Polonchuk; Erick M Carreira
Journal:  Angew Chem Int Ed Engl       Date:  2006-11-27       Impact factor: 15.336

Review 2.  Fragment-based lead discovery: a chemical update.

Authors:  Daniel A Erlanson
Journal:  Curr Opin Biotechnol       Date:  2006-11-03       Impact factor: 9.740

3.  Synthesis and evaluation of a new polymer-supported pseudoephedrine auxiliary for asymmetric alkylations on solid phase.

Authors:  Andrea M McGhee; Jean-Claude Kizirian; David J Procter
Journal:  Org Biomol Chem       Date:  2007-02-19       Impact factor: 3.876

4.  Fragment-based lead discovery grows up.

Authors:  Monya Baker
Journal:  Nat Rev Drug Discov       Date:  2013-01       Impact factor: 84.694

Review 5.  Fragment-based lead discovery and design.

Authors:  Diane Joseph-McCarthy; Arthur J Campbell; Gunther Kern; Demetri Moustakas
Journal:  J Chem Inf Model       Date:  2014-02-19       Impact factor: 4.956

6.  Kinetic resolution of racemic amino alcohols through intermolecular acetalization catalyzed by a chiral Brønsted acid.

Authors:  Takuto Yamanaka; Azusa Kondoh; Masahiro Terada
Journal:  J Am Chem Soc       Date:  2015-01-14       Impact factor: 15.419

7.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

8.  Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases.

Authors:  K Shankaran; Karla L Donnelly; Shrenik K Shah; Charles G Caldwell; Ping Chen; William K Hagmann; Malcolm Maccoss; John L Humes; Stephen G Pacholok; Theresa M Kelly; Stephan K Grant; Kenny K Wong
Journal:  Bioorg Med Chem Lett       Date:  2004-12-06       Impact factor: 2.823

9.  Synthesis and antibacterial activities of novel oxazolidinones having cyclic sulfonamide moieties.

Authors:  Seong Jong Kim; Seoung Jong Kim; Myung-Ho Jung; Kyung Ho Yoo; Jung-Hyuck Cho; Chang-Hyun Oh
Journal:  Bioorg Med Chem Lett       Date:  2008-09-11       Impact factor: 2.823

10.  Unravelling a new class of chiral organocatalyst for asymmetric ring-opening reaction of meso epoxides with anilines.

Authors:  Manish Kumar; Rukhsana I Kureshy; S Saravanan; Shailesh Verma; Ajay Jakhar; Noor-ul H Khan; Sayed H R Abdi; Hari C Bajaj
Journal:  Org Lett       Date:  2014-05-14       Impact factor: 6.005

View more
  6 in total

Review 1.  Chemical probes and drug leads from advances in synthetic planning and methodology.

Authors:  Christopher J Gerry; Stuart L Schreiber
Journal:  Nat Rev Drug Discov       Date:  2018-04-13       Impact factor: 84.694

2.  Multimodal small-molecule screening for human prion protein binders.

Authors:  Andrew G Reidenbach; Michael F Mesleh; Dominick Casalena; Sonia M Vallabh; Jayme L Dahlin; Alison J Leed; Alix I Chan; Dmitry L Usanov; Jenna B Yehl; Christopher T Lemke; Arthur J Campbell; Rishi N Shah; Om K Shrestha; Joshua R Sacher; Victor L Rangel; Jamie A Moroco; Murugappan Sathappa; Maria Cristina Nonato; Kong T Nguyen; S Kirk Wright; David R Liu; Florence F Wagner; Virendar K Kaushik; Douglas S Auld; Stuart L Schreiber; Eric Vallabh Minikel
Journal:  J Biol Chem       Date:  2020-07-28       Impact factor: 5.157

3.  Iridium-Catalyzed Enantioselective and Diastereoselective Hydrogenation of 1,3-Disubstituted Isoquinolines.

Authors:  Alexia N Kim; Aurapat Ngamnithiporn; Eric R Welin; Martin T Daiger; Christian U Grünanger; Michael D Bartberger; Scott C Virgil; Brian M Stoltz
Journal:  ACS Catal       Date:  2020-02-10       Impact factor: 13.084

4.  Divergent Synthesis and Real-Time Biological Annotation of Optically Active Tetrahydrocyclopenta[c]pyranone Derivatives.

Authors:  Shawn D Nelson; Mathias J Wawer; Stuart L Schreiber
Journal:  Org Lett       Date:  2016-12-07       Impact factor: 6.005

5.  Design and Synthesis of 56 Shape-Diverse 3D Fragments.

Authors:  Thomas D Downes; S Paul Jones; Hanna F Klein; Mary C Wheldon; Masakazu Atobe; Paul S Bond; James D Firth; Ngai S Chan; Laura Waddelove; Roderick E Hubbard; David C Blakemore; Claudia De Fusco; Stephen D Roughley; Lewis R Vidler; Maria Ann Whatton; Alison J-A Woolford; Gail L Wrigley; Peter O'Brien
Journal:  Chemistry       Date:  2020-07-08       Impact factor: 5.236

Review 6.  Recent Applications of Diversity-Oriented Synthesis Toward Novel, 3-Dimensional Fragment Collections.

Authors:  Sarah L Kidd; Thomas J Osberger; Natalia Mateu; Hannah F Sore; David R Spring
Journal:  Front Chem       Date:  2018-10-16       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.